Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma

No head-to-head trials have compared the efficacy of tisagenlecleucel vs historical treatments for adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study indirectly compared the overall survival (OS) and overall response rate (ORR) associated with tisagenlecleucel,...

Descripción completa

Detalles Bibliográficos
Autores principales: Maziarz, Richard T., Zhang, Jie, Yang, Hongbo, Chai, Xinglei, Yuan, Chengbo, Schwarz, Elisabeth, Jakovac, Mihael, Martinez-Prieto, Marcela, Agarwal, Abhijit, Degtyarev, Evgeny, Tam, Constantine, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043930/
https://www.ncbi.nlm.nih.gov/pubmed/35030634
http://dx.doi.org/10.1182/bloodadvances.2021006280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043930/
https://www.ncbi.nlm.nih.gov/pubmed/35030634
http://dx.doi.org/10.1182/bloodadvances.2021006280

Ejemplares similares